Harnessing Ferroptosis to Overcome Drug Resistance in Colorectal Cancer: Promising Therapeutic Approaches
- PMID: 37958383
- PMCID: PMC10649072
- DOI: 10.3390/cancers15215209
Harnessing Ferroptosis to Overcome Drug Resistance in Colorectal Cancer: Promising Therapeutic Approaches
Abstract
Drug resistance remains a significant challenge in the treatment of colorectal cancer (CRC). In recent years, the emerging field of ferroptosis, a unique form of regulated cell death characterized by iron-dependent lipid peroxidation, has offered new insights and potential therapeutic strategies for overcoming drug resistance in CRC. This review examines the role of ferroptosis in CRC and its impact on drug resistance. It highlights the distinctive features and advantages of ferroptosis compared to other cell death pathways, such as apoptosis and necrosis. Furthermore, the review discusses current research advances in the field, including novel treatment approaches that target ferroptosis. These approaches involve the use of ferroptosis inducers, interventions in iron metabolism and lipid peroxidation, and combination therapies to enhance the efficacy of ferroptosis. The review also explores the potential of immunotherapy in modulating ferroptosis as a therapeutic strategy. Additionally, it evaluates the strengths and limitations of targeting ferroptosis, such as its selectivity, low side effects, and potential to overcome resistance, as well as challenges related to treatment specificity and drug development. Looking to the future, this review discusses the prospects of ferroptosis-based therapies in CRC, emphasizing the importance of further research to elucidate the interaction between ferroptosis and drug resistance. It proposes future directions for more effective treatment strategies, including the development of new therapeutic approaches, combination therapies, and integration with emerging fields such as precision medicine. In conclusion, harnessing ferroptosis represents a promising avenue for overcoming drug resistance in CRC. Continued research efforts in this field are crucial for optimizing therapeutic outcomes and providing hope for CRC patients.
Keywords: colorectal cancer (CRC); drug resistance; ferroptosis; immunotherapy; treatment strategies.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Advancing the frontiers of colorectal cancer treatment: harnessing ferroptosis regulation.Apoptosis. 2024 Feb;29(1-2):86-102. doi: 10.1007/s10495-023-01891-9. Epub 2023 Sep 26. Apoptosis. 2024. PMID: 37752371 Review.
-
Ferroptosis in colorectal cancer: a future target?Br J Cancer. 2023 Apr;128(8):1439-1451. doi: 10.1038/s41416-023-02149-6. Epub 2023 Jan 26. Br J Cancer. 2023. PMID: 36703079 Free PMC article. Review.
-
Targeting ferroptosis regulators by natural products in colorectal cancer.Front Pharmacol. 2024 May 27;15:1374722. doi: 10.3389/fphar.2024.1374722. eCollection 2024. Front Pharmacol. 2024. PMID: 38860170 Free PMC article. Review.
-
Ferroptosis-based nano delivery systems targeted therapy for colorectal cancer: Insights and future perspectives.Asian J Pharm Sci. 2022 Aug;17(5):613-629. doi: 10.1016/j.ajps.2022.09.002. Epub 2022 Oct 1. Asian J Pharm Sci. 2022. PMID: 36382305 Free PMC article. Review.
-
Interaction mechanisms between autophagy and ferroptosis: Potential role in colorectal cancer.World J Gastrointest Oncol. 2023 Jul 15;15(7):1135-1148. doi: 10.4251/wjgo.v15.i7.1135. World J Gastrointest Oncol. 2023. PMID: 37546557 Free PMC article. Review.
Cited by
-
Enhancing Colorectal Cancer Immunotherapy: The Pivotal Role of Ferroptosis in Modulating the Tumor Microenvironment.Int J Mol Sci. 2024 Aug 23;25(17):9141. doi: 10.3390/ijms25179141. Int J Mol Sci. 2024. PMID: 39273090 Free PMC article. Review.
-
Non-coding RNA: A key regulator in the Glutathione-GPX4 pathway of ferroptosis.Noncoding RNA Res. 2024 May 20;9(4):1222-1234. doi: 10.1016/j.ncrna.2024.05.007. eCollection 2024 Dec. Noncoding RNA Res. 2024. PMID: 39036600 Free PMC article. Review.
-
Genipin's potential as an anti-cancer agent: from phytochemical origins to clinical prospects.Med Oncol. 2024 Jun 25;41(8):186. doi: 10.1007/s12032-024-02429-y. Med Oncol. 2024. PMID: 38918260 Review.
-
The Puzzle of Aspirin and Iron Deficiency: The Vital Missing Link of the Iron-Chelating Metabolites.Int J Mol Sci. 2024 May 9;25(10):5150. doi: 10.3390/ijms25105150. Int J Mol Sci. 2024. PMID: 38791185 Free PMC article. Review.
References
-
- Martini G., Ciardiello D., Vitiello P.P., Napolitano S., Cardone C., Cuomo A., Troiani T., Ciardiello F., Martinelli E. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? Cancer Treat. Rev. 2020;86:102023. doi: 10.1016/j.ctrv.2020.102023. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources